Esophagectomy is still the mainstream multidisciplinary treatment for esophageal cancer in combination with chemoradiotherapy. Anastomotic leakage (AL) after esophagectomy is one of the most dreaded postoperative complications, and is responsible for higher postoperative morbidity and mortality rates, prolonged hospital stays, and the need for further surgical procedures. Anastomotic tension, location of anastomosis, surgical technique, and postoperative factors, are modifiable factors when AL is concerned, and many efforts have been made to decrease AL in the last decades. Vascular perfusion to the anastomotic regions is considered to be the main driving force of AL. As a means of evaluating blood flow, indocyanine green (ICG) fluorescence angiography (FA) has recently been introduced to provide real-time assessment of the anastomosis area during esophagectomy. As a randomized control trial, the aim of our study was to assess the efficacy of ICG fluorescence angiography in the reduction of AL rates in minimally invasive esophagectomy (MIE). Research Hypothesis being - Indocyanine green Fluorescence Angiography is a potentially promising method to assess gastric conduit’s vascular perfusion during minimally invasive esophagectomy in real time, useful for deciding the site of anastomosis thereby decreasing the rate of anastomotic leakage compared to the conventional clinical method of deciding the site of anastomosis. The research question being Does Fluorescent Imaging using Indocyanine Green during Minimally Invasive Esophagectomy help decreasing Surgical Morbidity and changing the Surgical Plan? Aim: To study the effect of adding Florescent Imaging using Indocyanine Green during Minimally Invasive Surgery for Oesophageal Cancer on surgical morbidity and ultimately, the surgical plan. Primary Objective: To evaluate the efficacy of ICG use in the intraoperative period in minimally invasive esophagectomy, in decreasing the anastomotic leak rates after esophagectomy. Secondary Objectives: To study the use of ICG during minimally invasive esophagectomy in bringing about a change in surgical planning. To evaluate the operative time, blood loss, time until restoration of fluid diet, length of hospital stay, postoperative complications after the use of ICG fluorescence angiography during the intraoperative period of minimally invasive esophagectomy. To develop a standardized operative procedure of ICG use in oesophageal surgeries. Study design: Single centre, phase 2 randomized controlled trial with allocation ratio of 1:1.  Inclusion criteria - Patients aged 18 years patients or older. Histologically confirmed resectable primary squamous cell carcinoma/adenocarcinoma of the oesophagus/GEJ candidates Exclusion criteria - Patients not willing for the participation in the present study. Patients with a previous history of lung cancer, severe comorbidities, distant metastasis, combined multivisceral resectionllergic hypersensitivity to ICG or iodine. Sample size:  Significance level- 0.05; Power- 90%, Allocation ratio- 1:1. Expected leak in the test group - 5% and Expected leak in the control group- 15%, - Sample Size in each arm is 20 (total 40). Study duration: The study shall be conducted from August 2023 to November 2025. Parameters: Age, sex, BMI, comorbidities, history of smoking, history of drinking, American Society of Anaesthesiologists (ASA) grading, histopathology details, and tumour location. Pre-therapy staging workup, Upper gastrointestinal endoscopy findings, information on preoperative therapies, including neoadjuvant radiotherapy (NRC), neoadjuvant chemotherapy (NAC), and  Operative parameters like the type of primary surgery, technique (McKeown’s/Ivor-Lewis’), extent of Lymphadenectomy (Two/Three Field, duration of Surgery (hours), intraoperative blood loss (ml), fluid diet time (days), conventional anastomotic site from the pylorus (distance in cm), ICG Watershed (distance in cm from pylorus), ICG induced anastomotic site revision (distance in cm from pylorus) and difference between revision site and original site will be recorded. Postoperative outcomes and complications assessed up to 30 days after the index surgery.  Secondary outcome parameters include operative time, blood loss, time until restoration of fluid diet, length of hospital stay and postoperative complications other than an anastomotic leak.  EORTC Quality of Life Questionnaire for Esophago-gastric cancers. Timeline - Ethical approval and CTRI registration. Data collecting will be done in next one and half year. Data analysis will be done by November 2025